Al‐Rawashde et al. (2022) examined the potential anti‐leukemic properties of thymoquinone (TQ), a compound derived from Nigella sativa, specifically on acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) cells by targeting the JAK/STAT and PI3K/Akt/mTOR signaling pathways. The gene discussed is PIK3CA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.